Clinical trials in Magdeburg – page 16

251 clinical trials in Magdeburg, Germany across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Magdeburg at a glance

251

clinical trials

Research sites4

Quick filters

251 trials in Magdeburg

Open in trial search

Adenocarcinoma gastric+1

Not recruiting

Study Comparing Ramucirumab with Irinotecan, Leucovorin, and 5-FU or Paclitaxel for Patients with Advanced Stomach or Gastroesophageal Cancer After Previous Chemotherapy

Registered drugNo placebo

Study Comparing Ramucirumab with Irinotecan, Leucovorin, and 5-FU or Paclitaxel for Patients with Advanced Stomach or Gastroesophageal Cancer After Previous Chemotherapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Contact Research Centre

Rectal cancer

Not recruiting

Study Comparing FOLFOX Before Surgery to Risk-Adapted Chemotherapy After Surgery for Patients with Locally Advanced Rectal Cancer and Low Risk of Local Failure

Registered drugNo placebo

Study Comparing FOLFOX Before Surgery to Risk-Adapted Chemotherapy After Surgery for Patients with Locally Advanced Rectal Cancer and Low Risk of Local Failure

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Heidelberg University

Contact Research Centre

Central nervous system lymphoma

Not recruiting

Study on De-escalated Induction Therapy with Methotrexate, Cytarabine, Thiotepa, and Rituximab for Newly Diagnosed Primary CNS Lymphoma Patients

Registered drugNo placebo

Study on De-escalated Induction Therapy with Methotrexate, Cytarabine, Thiotepa, and Rituximab for Newly Diagnosed Primary CNS Lymphoma Patients

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Busulfan
Sponsor:Klinikum Der Landeshauptstadt Stuttgart gKAöR

Contact Research Centre

Colitis ulcerative

Not recruiting

Study on the Effects of Fecal Microbiome and Fecal Microbiome Filtrate Capsules for Patients with Active Ulcerative Colitis

Registered drug

Study on the Effects of Fecal Microbiome and Fecal Microbiome Filtrate Capsules for Patients with Active Ulcerative Colitis

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Metronidazole
Sponsor:Friedrich-Schiller-Universitaet Jena

Contact Research Centre

B-cell lymphoma

Not recruiting

Study of Rituximab, Polatuzumab Vedotin, and Glofitamab for Untreated Aggressive B-cell Lymphoma in Patients Over 60 Not Eligible for Full R-CHOP

Registered drugNo placebo

Study of Rituximab, Polatuzumab Vedotin, and Glofitamab for Untreated Aggressive B-cell Lymphoma in Patients Over 60 Not Eligible for Full R-CHOP

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Glofitamab
Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Contact Research Centre

Acute myeloid leukaemia+1

Not recruiting

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Enasidenib Mesilate
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Oesophageal adenocarcinoma

Not recruiting

Study comparing chemotherapy with or without radiation therapy in patients with resectable gastroesophageal junction cancer using docetaxel, oxaliplatin, fluorouracil and calcium folinate

Registered drugNo placebo

Study comparing chemotherapy with or without radiation therapy in patients with resectable gastroesophageal junction cancer using docetaxel, oxaliplatin, fluorouracil and calcium folinate

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Heidelberg University

Contact Research Centre

Bladder cancer

Not recruiting

Study of Pembrolizumab and Enfortumab Vedotin with Surgery vs. Surgery Alone for Patients with Muscle-Invasive Bladder Cancer Who Cannot or Choose Not to Use Cisplatin

Registered drugNo placebo

Study of Pembrolizumab and Enfortumab Vedotin with Surgery vs. Surgery Alone for Patients with Muscle-Invasive Bladder Cancer Who Cannot or Choose Not to Use Cisplatin

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Enfortumab Vedotin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

B-cell lymphoma+2

Not recruiting

Study Comparing Polatuzumab Vedotin with Rituximab, Ifosfamide, Carboplatin, and Etoposide for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo

Study Comparing Polatuzumab Vedotin with Rituximab, Ifosfamide, Carboplatin, and Etoposide for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:GWT-Tud GmbH

Contact Research Centre

Asthma

Not recruiting

Study on Long-Term Safety of Depemokimab for Adults and Adolescents with Severe Eosinophilic Asthma

InvestigationalNo placebo

Study on Long-Term Safety of Depemokimab for Adults and Adolescents with Severe Eosinophilic Asthma

InvestigationalNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Depemokimab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Acute myeloid leukaemia

Not recruiting

Study Comparing Standard Chemotherapy with CPX-351 for Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) and Intermediate or Adverse Genetics

Registered drugNo placebo

Study Comparing Standard Chemotherapy with CPX-351 for Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) and Intermediate or Adverse Genetics

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Cytarabine
Sponsor:Universitaetsklinikum Ulm AöR

Contact Research Centre

Hepatocellular carcinoma

Not recruiting

Study of Nivolumab for Patients with Liver Cancer at High Risk of Recurrence After Surgery or Ablation

Registered drug

Study of Nivolumab for Patients with Liver Cancer at High Risk of Recurrence After Surgery or Ablation

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Nivolumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Magdeburg

What the registry says about research in the country

01 Oncology Research

Clinical investigations focusing on innovative treatments for various cancer types, including breast cancer, lymphoma, and pancreatic cancer. Studies evaluate new therapeutic approaches and combination treatments.

HER2-positive metastatic breast cancer therapies
Diffuse Large B-Cell Lymphoma treatments
Advanced pancreatic cancer interventions

Particular emphasis on targeted therapies and immunotherapy approaches for better patient outcomes.

02 Dermatology Studies

Research focusing on chronic skin conditions and innovative treatments for psoriasis and other dermatological disorders. Multiple trials investigating new therapeutic options.

Moderate to severe plaque psoriasis
Prurigo nodularis treatments
Lichen simplex chronicus management

Studies aim to improve quality of life through advanced therapeutic approaches.

03 Cardiovascular and Metabolic Research

Investigations into treatments for cardiovascular disease and metabolic disorders, including innovative approaches for managing hypertriglyceridemia and diabetes.

Cardiovascular risk reduction
Type 2 diabetes management
Lipid disorder treatments

Focus on preventive strategies and novel therapeutic interventions.

Back to Germany All countries